



Fortis Healthcare Limited
Support Office:
Tower A, Unitech Business Park,
Block - F, South City 1, Sector - 41,
Gurgaon, Haryana - 122001 (India)
Tel : 0124 492 1021
Fax : 0124 492 1041
Ambulance : 105010
E-mail : secretarial@fortishealthcare.com
Website : www.fortishealthcare.com

August 18, 2017

FHL/SEC/STEX/RR/2017-18

The National Stock Exchange of India Ltd.
Corporate Communications Department
"Exchange Plaza", 5th Floor,
Bandra-Kurla Complex, Bandra (East),
Mumbai – 400051
Scrip Symbol: FORTIS

BSE Limited
Corporate Services Department
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001
Scrip Code:532843

Sub: Disclosure(s) under Regulation 30

Dear Sir(s),

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Fortis Cancer Care Limited ("FCCL"), a step down subsidiary of the Company has entered into a memorandum of understanding ("MoU") with Lalitha Healthcare Private Limited ("LHPL"), another step down subsidiary of the Company, Dr. Lakshmi Narayana Raju, Ms. Lakshmi Priya, Mr. S. Venkataramana Raju (collectively the "**Promoters of LHPL**") and Anikrish Hospitals Private Limited, for, *inter alia*, sale of the entire shareholding held by FCCL, representing 79.43% of the total issued and paid up equity share capital of LHPL ("**FCCL Shares**"), to the Promoters of LHPL ("**Proposed Transaction**"). The MoU contemplates that FCCL, LHPL and the Promoters of LHPL will enter into a share purchase agreement ("**SPA**") for the sale of the FCCL Shares to the Promoters of LHPL.

Pursuant, to the consummation the Proposed Transaction the control and management of LHPL will be transferred to the Promoters of LHPL.

The detailed disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith as Annexure A.

This is for your kind information and records purposes.

Thanking you,

Yours Faithfully

For Fortis Healthcare Limited


Rahul Ranjan
Company Secretary
ACS17035



Annexure A
Disclosures as required under Regulation 30
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

S. No	Particulars	Description
1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year.	During the Financial Year 2016-17, there were no operations carried out in LHPL. Accordingly, there was no contribution by such entity to the listed entity.
2	Date on which the agreement for sale has been entered into	August 18, 2017 i.e. date of execution of the MoU (" Execution Date ").
3	The expected date of completion of sale/ disposal	120 days from the Execution Date.
4	Consideration received from such sale/ disposal	INR 6,44,596 (Indian Rupees Six Lacs Forty-Four Thousand Five Hundred and Ninety Six).
5	Brief details of the buyers and whether the buyers belong to the promoter group/ group companies. If yes, details thereof.	<p>The following are the buyers of the shares of FCCL in LHPL:</p> <p>DR. LAKSHMI NARAYANA RAJU, son of Mr. S. R. Sreenivasa Raju, resident of No. 788/E, 3rd Main Road, Vijayanagar 2nd Stage, Bangalore – 560040.</p> <p>MS. LAKSHMI PRIYA, wife of Mr. Lakshmi Narayana Raju, resident of No. 788/E, 3rd Main Road, Vijayanagar 2nd Stage, Bangalore - 560 040.</p> <p>MR. S. VENKATARAMANA RAJU, son of Mr. S. R. Sreenivasa Raju, resident of No. 788/E, 3rd Main Road, Vijayanagar 2nd Stage, Bangalore - 560 040.</p> <p>All of the above buyers form part of the promoter group of LHPL.</p>
6	Whether the transaction would fall within related party transactions. If yes, whether the same is done at 'arm's length'?	The transaction is a related party transaction which is at arm's length.
7	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/ merger, shall be disclosed by the listed entity for such slump sale.	Not applicable

